Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Leukemia 11Prostatic Neoplasms 9Breast Neoplasms 9Leukemia, Myeloid, Acute 8Leukemia, Lymphocytic, Chronic, B-Cell 7Neuroblastoma 6Myelodysplastic Syndromes 6Multiple Myeloma 6Melanoma 6Lymphoma 6Glioblastoma 6Ovarian Neoplasms 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Glioma 4Osteosarcoma 3Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 3Kidney Neoplasms 3Fallopian Tube Neoplasms 3Breast Neoplasms, Male 3Neoplasms, Plasma Cell 2Neoplasms 2Medulloblastoma 2Hodgkin Disease 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Wilms Tumor 1Uveal Melanoma 1Urinary Bladder Neoplasms 1

Interventions

Irinotecan 6Temozolomide 5Cyclophosphamide 5Vincristine 4Magnetic Resonance Spectroscopy 4Doxorubicin 4palbociclib 3X-Rays 3Phantoms, Imaging 3Gemcitabine 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2olaparib 2ivosidenib 2ganitumab 2eribulin 2cixutumumab 2cabozantinib 2abemaciclib 2Vemurafenib 2Specimen Handling 2Radiotherapy, Image-Guided 2Radiosurgery 2Peripheral Blood Stem Cell Transplantation 2Nuclear Medicine Department, Hospital 2Nivolumab 2LY3023414 2FANG vaccine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Sarcoma, Ewing × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT04238819 2026-03-02

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Eli Lilly and Company

Phase 1/2 Completed
47 enrolled 36 charts
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡